3 April 2020 in Molecular Cancer Research
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications: Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
7 November 2019 in Annals of Oncology
Breast cancer (BC) is found approximately at 1 million of new cases annually, and mortality reaches 400 thousand. Acquired resistance to tamoxifen limits adjuvant therapy`s potential to combat BC. Notably, up to 50% of ER+ BC cases fail to respond tamoxifen therapy. Elucidating molecular mechanisms of tamoxifen resistance development and transfer is important to develop novel therapies. New biomarkers indicating tamoxifen resistance are also to be found for proper development of precise therapies. Previously we have demonstrated the existence of tamoxifen resistance horizontal transfer at least particularly mediated by exosomes. The latter can carry microRNAs cargo. In this work using NGS approaches we investigated the changes of intracellular miRNA content between control cells and cells that acquired resistance to tamoxifen in 3 different ways: a) by prolonged cultivation of cells with tamoxifen (MCF7/T); b) by co-cultivation of MCF7 and MCF7/T (MCF7/R), and c) by cultivation of MCF7 with addition of exosomes derived from MCF7/R (MCF7/exoT). All three routes of tamoxifen resistance acquisition in vitro revealed selective changes in a few miRNA levels. There were 8 such miRNA found in MCF7/T cells (with p-value <0.05), 6 miRNAs in MCF7/R, and 5 miRNAs found in MCF7/exoT. Notably, these overlap in 3 miRNAs: miR-30a-5p, miR-484 and miR-1301-3p. Tamoxifen resistance was accompanied by upregulation of miR-30a-5p (∼ 5,2 fold) and downregulation of both miR-484 and miR-1301-3p (∼4,2 and 6,7 fold respectively). Intriguingly miR-30a-5p was also significantly elevated in the exosomes derived from resistant cells indicating this miRNA`s possible involvement into the resistance transfer. Tamoxifen resistance acquisition in vitro by MCF7 cells have revealed common patterns of changes in 3 miRNAs levels that can represent special biomarkers connected with tamoxifen resistance of breast cancer cells. The authors. Experiments were supported by Russian Science Foundation (17-75-10212 – experiments with tamoxifen-resistant cells; 19-15-00245 – experiments with exosomal miRNAs). All authors have declared no conflicts of interest.